FutureFuel (FF) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
11 May, 2026Executive summary
Revenue rose 82% year-over-year to $31.95 million, driven by strong growth in both chemical and biofuel segments, with new energy market products, regulatory clarity, and new customer wins supporting gains.
Net loss widened to $20.6 million, or $(0.47) per share, primarily due to derivative losses and non-recurring winter storm repair costs.
Adjusted EBITDA improved to a loss of $13.8 million from a loss of $16.1 million, reflecting better underlying operating performance despite headline losses.
New customer wins and a $25 million customer-funded capacity addition in Chemicals signal strong demand and asset optimization.
Financial highlights
Revenue: $31.95 million (up 82% year-over-year); Chemical revenue: $19.6 million (+109.6% YoY); Biofuel revenue: $12.3 million (+50.7% YoY).
Net loss: $20.6 million (vs. $18.1 million loss prior year); Loss per share: $(0.47) basic and diluted (vs. $(0.41) prior year).
Adjusted EBITDA: $(13.8) million (improved from $(16.1) million prior year).
Gross loss: $15.9 million (vs. $15.2 million prior year), impacted by $11.6 million in derivative losses and $3.2 million in storm-related impacts.
Cash and cash equivalents: $22.4 million as of March 31, 2026, down from $51.3 million at year-end 2025.
Outlook and guidance
Management anticipates positive Adjusted EBITDA for full-year 2026, excluding non-cash derivative timing differences.
Over 65% of 2026 capital spending expected to be customer-funded, supporting capacity expansion and recurring revenue streams.
Regulatory changes and new EPA blending mandates expected to drive improved demand and economics for Biofuels segment.
Domestic capacity utilization expected to reach 100% by 2027.
Anticipates ongoing volatility in biofuel markets due to commodity price swings and regulatory changes.
Latest events from FutureFuel
- Annual meeting to elect directors, approve pay, and ratify auditor, with board size reduced.FF
Proxy filing - Q2 2026 saw revenue surge 121% and a return to profitability, driven by robust Chemicals and Biofuels growth.FF
Q2 2026 - 2025 saw steep losses and revenue declines, but new plant investments and regulatory clarity support a 2026 rebound.FF
Q4 2025 - Annual meeting to elect directors, ratify auditor, and update governance and compensation.FF
Proxy Filing - Shareholders will elect directors, ratify a new auditor, and see board and leadership changes.FF
Proxy Filing - Q3 2025 revenue dropped 56% with a $9.3M net loss amid biofuel market and regulatory headwinds.FF
Q3 2025 - Q2 2025 revenue fell 51% and net loss reached $10.4M as biodiesel production was idled.FF
Q2 2025 - Q3 loss and cash decline driven by biofuel weakness, margin pressure, and special dividend.FF
Q3 2024 - Q2 net income reached $9.6M as margins improved despite lower revenue and market pressures.FF
Q2 2024